Patent intelligence · US
US 7923004
4-ethynyl pyrazole derivative compounds and methods for treatment of HCV
4-ethynyl pyrazole derivative compounds and methods for treatment of HCV
Patent details — US 7923004
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 12, 2011
- Expiration
- Apr 7, 2031
- Applicant
- XTL BIOPHARMACEUTICALS LTD.
- Claims
- 13
- CPC classes
- A61P, A61P31/12, A61P31/18, A61P43/00
Quick answer
US 7923004 (4-ethynyl pyrazole derivative compounds and methods for treatment of HCV) is held by XTL BIOPHARMACEUTICALS LTD.. Status: granted. Granted Apr 12, 2011. Expires Apr 7, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XTL BIOPHARMACEUTICALS LTD.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61P, A61P31/12, A61P31/18, A61P43/00
More from XTL BIOPHARMACEUTICALS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 8329703
Pyrazole compounds
granted -
US 8143276
4-thio substituted quinoline and naphthyridine compounds
granted -
US 8048889
3,4-disubstituted coumarin and quinolone compounds
granted -
US 7994360
Benzofuran compounds
granted -
US 6254867
Human monoclonal antibodies to the hepatitis B surface antigen
expired -
US 6146629
Human monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg)
expired
Frequently asked questions
What is US patent 7923004?
US 7923004 (4-ethynyl pyrazole derivative compounds and methods for treatment of HCV) is held by XTL BIOPHARMACEUTICALS LTD.. Status: granted. Granted Apr 12, 2011. Expires Apr 7, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7923004?
XTL BIOPHARMACEUTICALS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 7923004 expire?
Our index shows an expiration date of Apr 7, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.